The comparative safety of various intravenous iron preparations in chronic kidney disease patients.
作者： Ganguli Anirban , H.S. Kohli , Vivekanand Jha , K.L. Gupta , Vinay Sakhuja
DOI: 10.1080/08860220802134631
关键词:
摘要: The relative safety of parenteral iron preparations is a controversial issue in the management anemia chronic kidney disease (CKD), as direct head-to-head comparative trials are lacking. In this study, patients CKD were randomized to receive intravenous low molecular weight dextran (ID), sodium ferrigluconate complex (SFGC), and sucrose (IS) at doses infusion rates recommended by product manufacturer. One time test dose was used only for ID SFGC. A total 2,980 injections (n = 339) i.v. given, 49 (14.45% per patient) 56 adverse events (1.88% infusion) noted. Odds ratios (OR) serious drug (ADE; i.e., death, anaphylaxis, or suspected immuno-allergic events) patient not significant between vs. SFGC (3.566) IS (2.129), whereas that (7.594) highly (p 0.034). OR ADE exposure significantly higher (OR 5.670, p 0.0147) 7.799, < 0.001). No difference seen three groups terms non-serious ADEs. Drug discontinuation occurred more often with ID. who developed anaphylactoid reaction tolerated well.
informahealthcare.com参考文章(31)
P Geisser, M Baer, E Schaub, Structure/histotoxicity relationship of parenteral iron preparations. Drug Research. ,vol. 42, pp. 1439- 1452 ,(1992)
James T. McCarthy, Cynthia E. Regnier, Carrie L. Loebertmann, Erik J. Bergstralh, Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products. American Journal of Nephrology. ,vol. 20, pp. 455- 462 ,(2000) , 10.1159/000046199
Daniel W. Coyne, Franklin N. Adkinson, Allen R. Nissenson, Steven Fishbane, Rajiv Agarwal, Joseph W. Eschbach, Beckie Michael, Vaughn Folkert, Daniel Batlle, J. Richard Trout, Naomi Dahl, Pamela Myirski, Jur Strobos, David G. Warnock, Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients Kidney International. ,vol. 63, pp. 217- 224 ,(2003) , 10.1046/J.1523-1755.2003.00703.X
Steven Fishbane, Edward A. Kowalski, The Comparative Safety of Intravenous Iron Dextran, Iron Saccharate, and Sodium Ferric Gluconate Seminars in Dialysis. ,vol. 13, pp. 381- 384 ,(2000) , 10.1046/J.1525-139X.2000.00104.X
Atinder Panesar, Rajiv Agarwal, Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease American Journal of Kidney Diseases. ,vol. 40, pp. 924- 931 ,(2002) , 10.1053/AJKD.2002.36322
Roger D. Hamstra, Intravenous Iron Dextran in Clinical Medicine JAMA: The Journal of the American Medical Association. ,vol. 243, pp. 1726- 1731 ,(1980) , 10.1001/JAMA.1980.03300430028018
Chaim Charytan, Nathan Levin, Mourhege Al-Saloum, T. Hafeez, Suzanne Gagnon, David B. Van Wyck, Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. American Journal of Kidney Diseases. ,vol. 37, pp. 300- 307 ,(2001) , 10.1053/AJKD.2001.21293
Steven Fishbane, Virgiliu-Dan Ungureanu, John K. Maesaka, Charles J. Kaupke, Victoria Lim, Jay Wish, The safety of intravenous iron dextran in hemodialysis patients American Journal of Kidney Diseases. ,vol. 28, pp. 529- 534 ,(1996) , 10.1016/S0272-6386(96)90463-1
George R. Aronoff, William M. Bennett, Samuel Blumenthal, Chaim Charytan, J.Phillip Pennell, John Reed, Marcos Rothstein, James Strom, Anthony Wolfe, David Van Wyck, Jerry Yee, Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney International. ,vol. 66, pp. 1193- 1198 ,(2004) , 10.1111/J.1523-1755.2004.00872.X
James C Barton, Ellen H Barton, Luigi F Bertoli, Charlene H Gothard, Jennifer S Sherrer, Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. The American Journal of Medicine. ,vol. 109, pp. 27- 32 ,(2000) , 10.1016/S0002-9343(00)00396-X